GlobeNewswire: RenovaCare, Inc. Contains the last 10 of 35 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T19:01:03ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/05/03/2434777/0/en/RenovaCare-Announces-Termination-of-StemCell-Systems-R-D-Agreement.html?f=22&fvtc=4&fvtv=55186RenovaCare Announces Termination of StemCell Systems R&D Agreement2022-05-03T14:06:10Z<![CDATA[SCOTTSDALE, Ariz., May 03, 2022 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for isolating and spraying cells for the regeneration of skin and other organs and tissues, today announced the termination of its July 1, 2020 Strategic Research and Development Agreement with StemCell Systems GmbH (SCS) and the closure of the RenovaCare R&D Innovation Center in Berlin, Germany. This decision ceases on-going development of the prototype for the closed, automated Cell Isolation Device and the portable, disposable SkinGun™ spray device. Development may resume at SCS or other Contract Manufacturing Organizations, upon the availability of adequate funds.]]>https://www.globenewswire.com/news-release/2022/03/24/2409430/0/en/RenovaCare-Announces-Management-Changes.html?f=22&fvtc=4&fvtv=55186RenovaCare Announces Management Changes2022-03-24T12:30:00Z<![CDATA[SCOTTSDALE, Ariz., March 24, 2022 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for isolating and spraying cells for the regeneration of skin and other organs and tissues, today announced reductions in its management team to further streamline administrative expenses.]]>https://www.globenewswire.com/news-release/2022/03/09/2400314/0/en/RenovaCare-Provides-Clinical-and-Corporate-Update.html?f=22&fvtc=4&fvtv=55186RenovaCare Provides Clinical and Corporate Update2022-03-09T20:35:40Z<![CDATA[SCOTTSDALE, Ariz., March 09, 2022 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for isolating and spraying cells for the regeneration of skin and other organs and tissues, today announced that following the review of its research and corporate activities, the Company is taking steps to streamline its clinical, research and development, and administrative operations in order to reduce costs.]]>RenovaCare Provides Clinical and Corporate UpdateRenovaCare, Inc.https://www.globenewswire.com/news-release/2021/10/14/2314291/0/en/RenovaCare-Establishes-Leadership-Position-in-Cell-Isolation-and-Spray-Technology-with-Newly-Awarded-U-S-Patent.html?f=22&fvtc=4&fvtv=55186RenovaCare Establishes Leadership Position in Cell Isolation and Spray Technology with Newly Awarded U.S. Patent2021-10-14T12:30:00Z<![CDATA[SCOTTSDALE, Ariz., Oct. 14, 2021 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented cell therapy technologies for the regeneration of skin and tissues, today announced the award of a new SkinGun™ patent by the United States Patent and Trademark Office (US Patent No. 11,135,380). The latest RenovaCare patent demonstrates the Company’s commitment to developing new products and expanding its proprietary cell isolation and spray technology platforms to now include biologics and drug delivery.]]>RenovaCare Awarded New Patents for SkinGun™: Ultra-Gentle Cell Spray TechnologyRenovaCare Intellectual Property Updatehttps://www.globenewswire.com/news-release/2021/07/22/2267341/0/en/RenovaCare-Provides-Update-on-Clinical-Trial-for-the-SkinGun-and-CellMist-System-for-Wound-Healing.html?f=22&fvtc=4&fvtv=55186RenovaCare Provides Update on Clinical Trial for the SkinGun™ and CellMist™ System for Wound Healing2021-07-22T12:30:00Z<![CDATA[ROSELAND, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for the regeneration of skin and other organs and tissues, today provided an update on its clinical trial evaluating the safety and feasibility of the SkinGun™ and CellMist™ System to facilitate wound healing using skin cells obtained directly from the burn patient.]]>RenovaCare Provides Update on Clinical Trial for the CellMist™ & SkinGun™ SystemRenovaCare Clinical Trial Updatehttps://www.globenewswire.com/news-release/2021/06/07/2242735/0/en/RenovaCare-Clinical-Trial-to-Start-at-U-S-Burn-Centers.html?f=22&fvtc=4&fvtv=55186RenovaCare Clinical Trial to Start at U.S. Burn Centers 2021-06-07T12:30:00Z<![CDATA[ROSELAND, N.J., June 07, 2021 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), today announced that it is initiating a clinical trial at four burn centers in the United States. This follows the Company’s recent Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA).]]>RenovaCare Announces Start of Clinical Trials at U.S. Burn CentersRenovaCare Clinical Trial to Start at U.S. Burn Centershttps://www.globenewswire.com/news-release/2021/06/01/2239509/0/en/RenovaCare-Responds-to-SEC-Complaint.html?f=22&fvtc=4&fvtv=55186RenovaCare Responds to SEC Complaint2021-06-01T12:30:00Z<![CDATA[ROSELAND, N.J., June 01, 2021 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com) today announced that it intends to vigorously defend itself and its stockholders against allegations made by the U.S. Securities and Exchange Commission (“SEC”) in a civil complaint filed on May 28, 2021 regarding legacy events (the “Complaint”) from over 3 years ago.]]>RenovaCare Responds to SEC ComplaintRenovaCare Responds to SEC Complainthttps://www.globenewswire.com/news-release/2021/05/06/2224571/0/en/FDA-Grants-RenovaCare-Full-IDE-Approval-for-Safety-and-Feasibility-Clinical-Trial.html?f=22&fvtc=4&fvtv=55186FDA Grants RenovaCare Full IDE Approval for Safety and Feasibility Clinical Trial2021-05-06T12:30:00Z<![CDATA[ROSELAND, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), today announced that its Investigational Device Exemption (IDE) application has been granted full approval by the U.S. Food and Drug Administration (FDA). This approval enables RenovaCare to conduct a clinical trial to evaluate the safety and feasibility of its SkinGun™ and CellMist™ System for the treatment of burn wounds using skin cells obtained directly from the burn patient.]]>FDA Grants RenovaCare Full IDE Approval for Safety and Feasibility Clinical TrialRenovaCare FDA IDE Approvalhttps://www.globenewswire.com/news-release/2021/03/30/2201592/0/en/RenovaCare-Announces-Organizational-Changes-and-Appointment-of-New-Officers.html?f=22&fvtc=4&fvtv=55186RenovaCare Announces Organizational Changes and Appointment of New Officers2021-03-30T12:30:00Z<![CDATA[ROSELAND, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of organs and tissues, announced today that its Chairman, Chief Executive Officer, and President, Mr. Alan Rubino, has decided to retire. “I am proud of all that has been accomplished at RenovaCare with our management team during my leadership tenure,” stated Mr. Rubino. “I wish the Company and its shareholders continued success as it prepares to commence its initial clinical studies.”]]>Dr. Kaiyo Nedd, Interim President & CEO, RenovaCare, Inc.Dr. Kaiyo Neddhttps://www.globenewswire.com/news-release/2021/02/25/2182484/0/en/RenovaCare-to-Present-at-H-C-Wainwright-Global-Life-Sciences-Conference-March-9-10-2021.html?f=22&fvtc=4&fvtv=55186RenovaCare to Present at H.C. Wainwright Global Life Sciences Conference March 9-10, 20212021-02-25T13:30:00Z<![CDATA[ROSELAND, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, announced today that the Company will present at the 2021 H.C. Wainwright Global Life Sciences Conference, scheduled for March 9 – 10.]]>RenovaCare to Present at H.C. Wainwright 2021 Global Life Sciences ConferenceRenovaCare CellMist™ and SkinGun™ System